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Background 
 
Uterine fibroids are benign, smooth muscle tumours in the uterus (womb) and occur in up to 
40% of women aged over 35 years. For some, these are asymptomatic and do not require 
treatment, but up to 50% of women affected can experience symptoms including heavy 
menstrual bleeding (leading to anaemia), dysmenorrhoea (painful periods), infertility and low 
quality of life. These women warrant treatment and the first choice intervention is surgery. 
Recently, medical therapies have been used pre-operatively to improve intra- and post-
operative outcomes. Fibroid growth is stimulated by oestrogen, by administering 
gonadotropin-hormone releasing analogues (GnRHa) the oestrogen is offset causing a 
reduction in uterine and fibroid size, therefore reducing the difficulty of the surgery, the risk of 
bleeding and other associated surgical complications. Other potential hormonal therapies 
include progestins, dopamine agonists and selective progesterone–receptor modulators 
(SPRMs). These therapies are only for short-term use due to their potential side effects 
including bone loss, plus they tend to be expensive.  
This review is an update of a previously published Cochrane Review published in 2000 and 
2001, with the scope broadened to include all preoperative medical treatments.  The relevance 
of this research to nursing relates to patient experience and service provision. The women 
undergoing these therapies have improved surgical outcomes, for example, reduced risk of 
haemorrhage and the need for more extensive surgery.  This will also reduce their need for 
longer hospitalisation 
 
Objective/s:  
 
This review aims to assess if giving pre-operative hormonal therapies for uterine fibroids 
improves surgical outcomes.  
 
Intervention/Methods:  
 
The reviewers gathered data by conducting searches of six prominent databases (Cochrane 
Gynaecology and Fertility Group specialised register, CENTRAL, MEDLINE, Embase, 
PsycINFO and CINAHL), trials registers (including the World Health Organisation portal and 
clinicaltrials.gov), theses, dissertations, unpublished or non-commercially published research. 
They contacted pharmaceutical companies to identify additional studies which met the 
inclusion criteria (comparison of medical therapies versus placebo, or no treatment, when 
administered before surgery for uterine fibroids). Surgeries included myomectomy (removal of 
fibroids from the uterus), hysterectomy (removal of the uterus) or endometrial resection. The 
studies included randomised controlled trials (RCTs) from all years up until June 2017 with no 
restriction on the language of publication. 
 
Trials where medical therapies were the sole treatment, without surgery, were excluded. 
 
The searches identified thirty-eight RCTs involving 3623 women. Interestingly, of the 38 
studies included, 14 were wholly or partially funded by pharmaceutical companies, 3 were 
funded by hospitals or institutions, and the funding source of the remaining 21 studies was 
unclear. Therefore it is not possible to state if conflict of interest influenced the results. 
 
Results: 
 
The use of GnRHa treatments showed a reduction in both fibroid and uterine size and an 
increase in pre-operative haemoglobin levels. During surgery for hysterectomy, there was 
found to be less blood loss (therefore, requiring fewer blood transfusions), less time in surgery 
(reduced by an average of 14 minutes) and fewer post-operative complications.  The results 
for those undergoing myomectomy showed less blood loss intraoperatively, but did not 
produce similar results for surgical time or post-surgical complications. However, the women 
reported an increased likelihood of experiencing unwanted hot flushes. The SPRM drug, 
ulipristal acetate, had similar results. 
 
The reviewers acknowledged the uncertainties associated with many of the findings, including 
potential bias, small trial size and the experience of the surgeon.  
 
Conclusions: 
 
This review suggests that the use of GnRHa and SPRM therapies prior to surgery for uterine 
fibroids is beneficial as they can reduce the complexity of the surgical procedure, lessen blood 
loss and decrease the incidence of anaemia. However, the review acknowledges that some 
women who received GnRHa experienced increased frequency of hot flushes. This requires 
further investigation as the study sizes were small and the reviewers themselves stated that 
replication of these studies was advisable before firm conclusions could be made. Further 
exploration should also include identifying which women would benefit most from this therapy 
due to the cost implication, an increasing consideration in global healthcare provision (Appleby 
2013). The improvement of surgical outcomes is important to nursing as it improves the patient 
experience by reducing the risk of potential complications, which can be debilitating or fatal, 
and improves recovery time and the need for a prolonged hospital stay.  
 
Implications for Practice:  
 
There are assumed benefits for the use of GnRHa and ulipristal acetate therapies prior to 
surgery although these need further investigation on a larger scale. In the United Kingdom, 
the National Institute for Health and Care Excellence (NICE) has removed the use of ulipristal 
acetate as a first line treatment for heavy menstrual bleeding on the advice of the European 
Medicines Agency which has introduced temporary safety measures to include performing at 
least monthly liver function tests on all existing patients (NICE 2018). This could be with 
prolonged use which the study was not advocating, therefore, further research is required to 
establish the role these medical therapies can play in improving the outcomes of women being 
treated for uterine fibroids.  
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